Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders Biotech Investing
Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025 Biotech Investing
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 Biotech Investing
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study Nanotech Investing
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet Biotech Investing
Incyte Announces Phase 1 Results for its TGF?R2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma Biotech Investing
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Biotech Investing
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 Biotech Investing
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology Congress Biotech Investing
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 Biotech Investing
